Nordic HIV & Virology Conference

• (O1) Switching from Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate Improves Lipid Profile and Protects from Weight Gain
• (O2) Altered cell cycling and apoptosisis in colonic mucosa of immunological nonresponders
• (O3) Novel dual mechanism of action of natural occurring anti-HIV-1 dipeptide
• (O4) Monkeypox at Venhälsan, Södersjukhuset, Stockholm during May – August 2022: clinical aspects and observations
• (O5) Anamnestic expansion of Omicron-reactive CD8+ T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states
• (O6) Durability of neutralization titers following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination – the CVIC study
• (P1) Expression of microRNAs is dysregulated by HIV while tuberculosis drives alterations of small nucleolar RNAs in HIV-positive adults with tuberculosis
• (P2) Psychosocial, sexual and physical health in women with and without HIV in Denmark: a nationwide cross-sectional study.
• (P3) Molecular epidemiology of HIV-1 in Eastern Europe and Russia
• (P4) Length of stay in Denmark before HIV diagnosis and linkage to care: a population-based study of migrants linked to Danish HIV care 1995-2020
• (P5) Presence and Function of Follicular CD8+ T cells in HIV Infection
• (P6) HIV immunological non-responders after viral suppression: prevalence and associated factors investigated in a low pre-ART Nadir CD4 population
• (P7) Hierarchical clustering and trajectory analyses reveal viremia-independent B-cell perturbations in HIV-2 infection
• (P8) Burden and risk factors of sexually transmitted infections before and after HIV diagnosis in a Finnish national HIV cohort 1995-2019
• (P9) Impact of joint cervical cancer screening and HIV follow-up care on adherence to cervical cancer screening guidelines in women living with HIV
• (P10) A ten-week follow-up of a Swedish monkeypox case part of the 2022 multinational outbreak
• (P11) Case report on the outcome of a co-infection with human monkeypox virus and COVID-19 in a patient with a well-managed HIV infection in Latvia.
• (P12) Long term persistence of anti-HBs antibodies after vaccination with a 3-antigen HBV vaccine compared to a single-antigen HBV vaccine
• (P13) Hepatitis E virus Infection, a risk for liver transplant recipients in Sweden
• (P14) Antiviral treatment cessation in HBeAg negative chronic hepatitis B: clinical outcome is associated with increase in pro-inflammatory cytokines
• (P15) Prevalence, risk factors, treatment uptake and outcome of Hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala
• (P16) Human coronavirus OC43 and cross-reactive SARS-CoV-2 CD4+ T cell immunity in children
• (P17) Gender difference in circulating sACE2 protein in moderate and severe COVID-19 and healthy controls
• (P18) Cross-reactive CD4+ T cell immunity to pandemic SARS-CoV-2 in relation to endemic human coronavirus (HCoV)-OC43 infections throughout life
• (P19) COVID-19 hospitalization outcomes in adults by HIV-status; a nation-wide register-based study
• (P20) Impact of gut microbiome on immunological response to COVID-19 vaccination.
• (P21) Dynamic MAIT cell recovery after severe COVID-19 is transient with functional anomalies